Highlights on head & neck cancer
With their combined knowledge and experience, Prof. Paul Clement and Prof. Jean-Pascal Machiels offer valuable insights into head & neck cancer research and treatment advancements.
Firstly, they discussed data from a real-world analysis of PD-L1 expression testing patterns in recurrent/metastatic head and neck squamous cell carcinoma.
In locoregionally-advanced nasopharyngeal carcinoma, the CONTINUUM trial was discussed, evaluating PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy versus IC-CCRT. In patients with recurrent, metastatic head and neck squamous cell carcinoma, results of the multicenter phase II FRAIL-IMMUNE trial with the combination of durvalumab and weekly paclitaxel carboplatin was analysed by both experts, as well as the dose-expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab.
They concluded with data from the ICoLP study evaluating immuno-chemotherapy as single treatment modality for larynx preservation.
With the educational support of:
